证券代码：688089 证券简称：嘉必优 公告编号：2025-042 嘉必优生物技术（武汉）股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 29 日 （二） 股东大会召开的地点：湖北省鄂州市葛店开发区创业大道 3 号嘉必优葛 店分公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 表决情况： | 1、出席会议的股东和代理人人数 | 92 | | --- | --- | | 普通股股东人数 | 92 | | 2、出席会议的股东所持有的表决权数量 | 72,545,745 | | 普通股股东所持有表决权数量 | 72,545,745 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 43.3057 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 4 ...

北京市中伦律师事务所 关于嘉必优生物技术（武汉）股份有限公司 2024 年年度股东大会的 法律意见书 致：嘉必优生物技术（武汉）股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》《中华人民共和国律师法》《上市公司股东大会规则》（以下简称"《股东 大会规则》"）等相关法律、法规、规章、规范性文件及《嘉必优生物技术（武汉） 股份有限公司章程》（以下简称"《公司章程》"）的规定，北京市中伦律师事务所 （以下简称"本所"）受嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"或"嘉必优"）的委托，对公司 2024 年年度股东大会（以下简称"本次股东 大会"）出具本法律意见书。 为出具本法律意见书，本所委派律师参加了本次股东大会，审查了公司提供 的文件和资料，并进行了必要的审查和验证。在前述审查和验证的过程中，本所 律师得到公司的如下承诺和保证：公司已经提供了本所认为出具本法律意见书所 必需的，完整、真实、准确、合法及有效的原始书面材料、副本材料、复印件或 口头证言，所有副本材料或复印件与原件一致，无任何隐瞒、虚假和重大遗漏之 处。 为出具本法律意见书，本所律师谨作如下声 ...

Summary of the Conference Call for 嘉必优 Company Overview - 嘉必优 is experiencing growth in the domestic market due to the completion of new national standards and demographic factors, with increased demand for algal oil DHA from core customers, particularly in infant formula products [2][3][5] Key Points Domestic Market Performance - Revenue growth is driven by major clients like 伊利 and 完达山, with significant increases in their purchase volumes [2][7][6] - The proportion of algal oil DHA in infant formula is rising, leading to a notable increase in demand for this product [3][5] - The company expects stable revenue growth due to the ongoing demand from these core clients [6] International Market Strategy - 嘉必优 is focusing on expanding its international client base, particularly through European distributors, with a goal to increase market share for ARA products and promote algal oil DHA and HMO [2][4][22] - The market share in the supply chains of major international clients has increased from 10% to 15%-20%, with a target of reaching 30% [3][22] Product Performance and Profitability - In Q1 2025, profit growth outpaced revenue growth due to optimized product and customer structures, with a higher proportion of high-margin products [4][27] - The company anticipates stable profitability for the year, despite variations in client performance [4][27] Future Growth Opportunities - The company is exploring applications for ARA and DHA beyond dairy products, including health supplements, animal nutrition, and cosmetics [12][13] - The trend towards high-end and differentiated products in the dairy sector presents new opportunities for growth [9][10] New Product Development - Expected high growth products for 2025 include ARA and DHA, driven by domestic clients' increased usage of algal oil DHA [18] - HMO products are also being developed, with some international clients already placing orders [26] Competitive Landscape - The main competitors for ARA are 罗盖特 and for algal oil DHA are 润科, with opportunities for market share growth due to competitors facing challenges [8] Market Trends - The demand for adult and elderly milk powder is increasing, particularly products that incorporate algal oil DHA, aligning with the aging population trend [11] Capacity and Production - The company has sufficient production capacity, with plans to expand further to meet market demand [28][29] Financial Outlook - The company aims for double-digit stable growth in 2025, maintaining its budget without adjustments [17] Additional Insights - The company is leveraging omics technology to enhance product efficacy and support downstream clients in the cosmetics sector [19][20] - The pet nutrition segment, while currently small, is being developed through innovative channels like pet hospitals [14][15][16] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting 嘉必优's growth trajectory and market positioning.

Summary of Company and Industry Insights Company Overview - The company is a microbial synthesis nutrient supplier focusing on two main sectors: "pet nutrition" and "cosmetics and personal care" [1] - The company has a comprehensive range of pet food products and is developing functional raw materials such as ergothioneine [1][2] - The company is actively pursuing an asset restructuring plan to enhance its foundational R&D capabilities [3] Core Insights - The new national standards for infant formula production and R&D are expected to accelerate market concentration towards leading companies with technological and product advantages [2] - The company has established stable and deep collaborations with major clients such as Feihe, Yili, Nestlé, Danone, and Cargill, which is contributing to a steady increase in market share as industry concentration rises [2] - In the pet nutrition sector, the company is developing product application solutions based on fatty acid balance theory, addressing health issues across different life stages of pets [2] - The cosmetics and personal care segment is a significant part of the company's business model, leveraging core technologies such as synthetic biology, omics technology, and permeation carrier technology to serve beauty clients [2] - The company is promoting products like nest extract while also considering the application of DHA, ARA, and β-carotene in the cosmetics sector [2] Financial and Strategic Developments - The company plans to acquire a 63.2134% stake in Shanghai Ouyi Biomedical Technology Co., Ltd. through a combination of share issuance and cash payment, with the project currently under review by the Shanghai Stock Exchange [3] - The acquisition is expected to enhance the company's foundational R&D capabilities, with a projected cumulative net profit of no less than 270 million yuan from the target company between 2025 and 2027 [3] - Analysts believe that the company's performance in Q1 2025 exceeded expectations due to the rapid advancement of new national standards and international markets [3] Risk Considerations - The insights provided are based on institutional exchanges with the listed company and do not constitute investment research opinions; information should be verified against official company announcements and analyst reports [1][3]

嘉必优生物技术(武汉)股份有限公司 本公司同意上述变更事项。 特此说明。 嘉必优生物技术 上海证券交易所: 嘉必优生物技术(武汉)股份有限公司于 2025年 3 月 20 日向贵所报送申 请,于2025年3月27日收到《关于受理嘉必优生物技术(武汉)股份有限公司 发行股份及支付现金购买资产并募集配套资金暨关联交易发行股份购买资产并 募集配套资金申请的通知》(上证科审(并购重组)(2025)6号)。本次变更前, 签字会计师为丁红远、夏雪,现拟变更为丁红远、付娟。 大信会计师事务所(特殊普通合伙)作为公司发行股份及支付现金购买资产 并募集配套资金暨关联交易的审计机构,原委派丁红远、夏雪为签字注册会计师, 鉴于原签字注册会计师夏雪因个人原因离职,根据相关规定委派丁红远、付娟为 签字注册会计师。 关于变更签字会计师的专项说明 ...

大信会计师事务所（特殊普通合伙）关于 嘉必优生物技术（武汉）股份有限公司发行股份购买资产并募集配套资金 暨关联交易变更签字注册会计师的承诺函 上海证券交易所： 一、基本情况 原担任本次并购重组的签字会计师夏雪因个人原因从本所离职，故不再担任本次并购重 组签字会计师。 付娟同意承担签字会计师职责,履行尽职调查义务,承诺对夏雪签署的相关文件均予以 认可并承担相应法律责任,并对今后签署材料的真实性、准确性、完整性承担相应法律责任。 本所对付娟的承诺进行复核,认为付娟已履行尽职调查义务,并出具专业意见,且与夏雪 的结论性意见一致。本所承诺对付娟签署的相关文件均予以认可并承担相应法律责任,确保 相关文件不存在虚假记载、误导性陈述和重大遗漏。 本次变更前，付娟已经是发行人本次并购重组审计的核心审计人员之一，同时,变更 过程中相关工作安排已有序交接。上述变更事项不会对发行人本次并购重组申请构成不利影 响,不会对本次并购重组申请构成障碍。 特此承诺。 嘉必优生物技术（武汉）股份有限公司（以下简称"上市公司"）于 2025 年 3 月 20 日 向贵所报送申请，于 2025 年 3 月 27 日被受理。大信会计师事务所（特殊普 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-041 嘉必优生物技术（武汉）股份有限公司 关于变更重大资产重组项目及 2025 年审计签字会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，嘉必优生物技术（武汉）股份有限公司（以下简称"公司"）收到大信 会计师事务所（特殊普通合伙）（以下简称"大信"）关于变更公司重大资产重组 项目及 2025 年审计签字注册会计师的通知。现将有关情况公告如下： 一、签字注册会计师变更情况 （一）重大资产重组项目 公司拟以发行股份及支付现金的方式向王树伟等 13 名交易对方购买上海欧 易生物医学科技有限公司 63.2134%的股权，并募集配套资金暨关联交易（以下 简称"本次交易"）的申请于 2025 年 3 月 20 日向上海证券交易所报送，于 2025 年 3 月 27 日被受理。 大信作为本次交易的审计机构，原委派丁红远、夏雪为签字注册会计师，鉴 于原签字注册会计师夏雪因个人原因离职，根据相关规定委派丁红远、付娟为签 字注册会计师。 具体内容详见公司同日在 ...

三、变更后签字人员基本情况 国泰海通证券股份有限公司 关于嘉必优重大资产重组项目变更签字会计师的专项说明 上海证券交易所： 一、基本情况 嘉必优生物技术（武汉）股份有限公司（（以下简称"上市公司"）于 2025 年 3 月 20 日向贵所报送申请，于 2025 年 3 月 27 日被受理。国泰海通证券股份有 限公司（以下简称"独立财务顾问"）接受上市公司委托，担任其发行股份及支 付现金购买资产并募集配套资金暨关联交易（以下简称"本次交易"）的独立财 务顾问。本次变更前，签字会计师为丁红远、夏雪，现拟变更为丁红远、付娟。 二、变更事由 大信会计师事务所（特殊普通合伙）作为公司发行股份及支付现金购买资产 并募集配套资金暨关联交易的审计机构，原委派丁红远、夏雪为签字注册会计师， 鉴于原签字注册会计师夏雪因个人原因离职，根据相关规定委派丁红远、付娟为 签字注册会计师。经核查，上述变更事由属实。 （以下无正文） 签字注册会计师：付娟，2020 年成为注册会计师，2015 年开始从事上市公 司审计业务，2020 年 10 月加入大信会计师事务所工作至今，承办过 IPO、上市 公司年报审计、发行债券审计、重大资产审计等证券 ...

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

证券代码：688089 证券简称：嘉必优 公告编号：2025-040 嘉必优生物技术(武汉)股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2024年年度股东大会 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025年5月29日 无 二、会议审议事项 本次股东大会审议议案及投票股东类型 ● 股东大会召开日期：2025年5月29日 ● 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 一、召开会议的基本情况 （一）股东大会类型和届次 （二）股东大会召集人：董事会 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 （四）现场会议召开的日期、时间和地点 召开日期时间：2025年5月29日 14点00分 召开地点：湖北省鄂州市葛店开发区创业大道3号嘉必优葛店分公司会议室 （五）网络投票的系统、起止日期和投票时间。 ■ 至2025年5月29日 采用上海证券交易所网络投票系统，通过交易系统投票平台的 ...